SunTrust Banks Inc. Analysts Give Fresenius Medical Care AG (FMS) a $48.00 Price Target
Fresenius Medical Care AG (NYSE:FMS) has been assigned a $48.00 price objective by SunTrust Banks Inc. in a report released on Thursday. The firm presently has a a “buy” rating on the stock. SunTrust Banks Inc.’s target price suggests a potential upside of 16.34% from the stock’s current price.
FMS has been the subject of a number of other reports. DZ Bank AG restated a “neutral” rating on shares of Fresenius Medical Care AG in a report on Friday, September 16th. Goldman Sachs Group Inc. restated a “buy” rating on shares of Fresenius Medical Care AG in a report on Tuesday, September 13th. Citigroup Inc. upgraded shares of Fresenius Medical Care AG from a “neutral” rating to a “buy” rating in a report on Tuesday, September 6th. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a report on Friday, July 8th. Finally, Berenberg Bank restated a “buy” rating on shares of Fresenius Medical Care AG in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $44.33.
Shares of Fresenius Medical Care AG (NYSE:FMS) traded up 1.31% during trading on Thursday, hitting $41.80. The stock had a trading volume of 94,669 shares. The stock’s 50-day moving average price is $43.87 and its 200 day moving average price is $43.82. Fresenius Medical Care AG has a one year low of $38.71 and a one year high of $47.52. The stock has a market cap of $25.56 billion, a price-to-earnings ratio of 23.17 and a beta of 0.58.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/suntrust-banks-inc-analysts-give-fresenius-medical-care-ag-fms-a-48-00-price-target.html
Fresenius Medical Care AG (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.04. Fresenius Medical Care AG had a net margin of 6.40% and a return on equity of 9.66%. The company earned $4.42 billion during the quarter, compared to analysts’ expectations of $4.54 billion. On average, equities analysts forecast that Fresenius Medical Care AG will post $2.01 EPS for the current year.
Several large investors have recently added to or reduced their stakes in FMS. Genesee Valley Trust Co. raised its position in Fresenius Medical Care AG by 1.6% in the third quarter. Genesee Valley Trust Co. now owns 7,833 shares of the company’s stock valued at $343,000 after buying an additional 121 shares during the period. Atria Investments LLC acquired a new position in Fresenius Medical Care AG during the third quarter valued at about $234,000. Creative Planning raised its position in Fresenius Medical Care AG by 4.7% in the third quarter. Creative Planning now owns 7,511 shares of the company’s stock valued at $329,000 after buying an additional 338 shares during the period. Searle & CO. acquired a new position in Fresenius Medical Care AG during the third quarter valued at about $998,000. Finally, Harding Loevner LP raised its position in Fresenius Medical Care AG by 40.8% in the third quarter. Harding Loevner LP now owns 3,332,640 shares of the company’s stock valued at $145,870,000 after buying an additional 966,390 shares during the period. Institutional investors and hedge funds own 2.33% of the company’s stock.
About Fresenius Medical Care AG
Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.
Receive News & Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related companies with MarketBeat.com's FREE daily email newsletter.